Table 4.
Cytotoxicity (%) enhancement on 4T1 and MCF-7 cells treated with various siRNAs (1 pM, 10 pM, 100 pM, 1 nM, and 10 nM) incorporated into an apatite structure formed with 3 mM of CaCl2. The data is presented as mean ± SD compared to free siRNA.
| Cell line | Treatment | siRNA Concentration | ||||
|---|---|---|---|---|---|---|
| 1 pM | 10 pM | 100 pM | 1 nM | 10 nM | ||
| 4T1 | CA/ERBB2 | 16.44 ± 5.77 | 33.24 ± 9.14 | 26.70 ± 3.93 | 28.09 ± 6.28 | 19.80 ± 1.13 |
| CA/AKT | 14.11 ± 5.41 | −4.58 ± 5.01 | 3.42 ± 1.23 | −3.27 ± 4.48 | −3.96 ± 2.98 | |
| CA/MAPK | 10.68 ± 3.69 | −0.72 ± 0.87 | 17.59 ± 1.04 | 5.36 ± 1.15 | 25.45 ± 4.64 | |
| CA/ROS1 | 13.85 ± 6.99 | 14.68 ± 3.87 | 27.46 ± 1.17 | 16.65 ± 1.44 | 35.56 ± 2.81 | |
| MCF-7 | CA/ERBB2 | 07.49 ± 8.01 | 24.56 ± 3.19 | 13.82 ± 3.34 | 19.29 ± 3.91 | 8.63 ± 1.67 |
| CA/ROS1 | 12.52 ± 2.79 | 13.69 ± 3.07 | 23.97 ± 2.13 | 28.88 ± 2.29 | 29.70 ± 3.96 | |